Nanoform

Activities: Drug Delivery Research & Development

Trending Articles

  1. FUJIFILM Biotechnologies launches ShunzymeX purification technology at Festival of Biologics The company has unveiled ShunzymeX, a precision downstream purification platform developed with the University of Edinburgh, designed to simplify complex biologics processing...
  2. Viatris to cut 10% of its global workforce after Indian plant fire Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected...
  3. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  4. Mastering precision: overcoming production hurdles for inhalable dry powder manufacturing From high-shear blending mechanics to the impact of particle size and distribution, this article explores the key factors that define effective inhalable powder formulations...
  5. CordenPharma Colorado expands peptide development capacity with lease of new lab Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

Related Content

Regulatory

Nanoform granted European Commercial cGMP Manufacturing Licence for APIs

The Finnish company is now authorised to manufacture nanoformed APIs for the European market and for countries in the Middle East and North Africa, Asia and the Americas, where mutual recognition applies to the European license
Finance

Nanoform collaborates with A.forall and IMGA to outlicence Nanoencorafenib

Nanoform will establish a new company, BRAFMed, to progress the clinical development and future outlicensing of the patient-centric nanoformulation of encorafenib
Research & Development

Nanoform and Takeda team up to advance plasma-derived therapy development

The collaboration will aim to develop plasma-derived therapeutics and accelerate the movement of potential medicines into the clinic
Research & Development

Apalutamide study demonstrates the advantages of nanoforming for cancer treatment

Nanoform’s technology delivers some of the world’s smallest nanoparticles at clinical and commercial scale
Research & Development

Nanoform announces clinical results for Enzalutamide cancer drug

The nanotechnology expert has announced promising clinical results for its Enzalutamide drug to treat prostate cancer
Research & Development

Nanoform commenced relative bioavailability study of nanotechnology enhanced enzalutamide

Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilising Nanoform’s platform technologies
Ingredients

Nanoform grants Global STARMAP AI License to AstraZeneca

Nanoform Finland, an innovative nanoparticle medicine-enabling company has announced that it has granted AstraZeneca Plc a global online STARMAP licence
Subscribe now